Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China

Colorectal cancer (CRC) is the third most prevalent cancer in China but few large-scale studies were conducted to understand CRC patients. The current study is aimed to gain a real-world perspectives of CRC patients in China. Using electronic medical records of sampled patients between 2011 and 2016...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2020-02, Vol.20 (1), p.131-131, Article 131
Main Authors: Xu, Ruihua, Wang, Wei, Zhu, Bo, Lin, Xiaoyan, Ma, Dong, Zhu, Lingjun, Zhao, Qingchuan, Nie, Yongzhan, Cai, Xiaohong, Li, Qi, Fang, Weijia, Li, Hongyan, Wang, Ning, Chen, Yun, Peng, Cike, Fang, Honghao, Shen, Lin
Format: Article
Language:English
Subjects:
5-Fluorouracil
Age
Biological products
Cancer
Cancer metastasis
Cancer patients
Cancer research
Cancer therapies
Care and treatment
Chemotherapy
China
Colorectal cancer
Colorectal carcinoma
Comparative analysis
Demography
Diseases
Electronic medical records
Electronic records
Epidemiology
Fluorouracil
Folinic acid
Hospitals
Insurance
Internal medicine
Irinotecan
Medical prognosis
Medical records
Medical research
Metastases
Metastasis
National health insurance
Oncology
Oxaliplatin
Patients
Population
Prognosis
Real-world evidence
Treatment patterns
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c625t-f26abf8c5dd500b275db09767fa85a582d795126362361de5dd0d0d8777969cb3
cites cdi_FETCH-LOGICAL-c625t-f26abf8c5dd500b275db09767fa85a582d795126362361de5dd0d0d8777969cb3
container_end_page 131
container_issue 1
container_start_page 131
container_title BMC cancer
container_volume 20
creator Xu, Ruihua
Wang, Wei
Zhu, Bo
Lin, Xiaoyan
Ma, Dong
Zhu, Lingjun
Zhao, Qingchuan
Nie, Yongzhan
Cai, Xiaohong
Li, Qi
Fang, Weijia
Li, Hongyan
Wang, Ning
Chen, Yun
Peng, Cike
Fang, Honghao
Shen, Lin
description Colorectal cancer (CRC) is the third most prevalent cancer in China but few large-scale studies were conducted to understand CRC patients. The current study is aimed to gain a real-world perspectives of CRC patients in China. Using electronic medical records of sampled patients between 2011 and 2016 from 12 hospitals in China, a retrospective cohort study was conducted to describe demographics and disease prognosis of CRC patients, and examine treatment sequences among metastatic CRC (mCRC) patients. Descriptive, comparative and survival analyses were conducted. Among mCRC patients (3878/8136, 48%), the fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and other oxaliplatin-based regimens were the most widely-used first-line treatment (42%). Fluorouracil, leucovorin, irinotecan (FOLFIRI) and other irinotecan-based regimens dominated the second-line (40%). There was no a dominated regimen for the third-line. The proportion of patients receiving chemotherapy with targeted biologics increased from less than 20% for the first- and second- lines to 34% for the third-line (p 
doi_str_mv 10.1186/s12885-020-6557-5
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a7cd504819dc47ea933001930f3da3ba</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A614246120</galeid><doaj_id>oai_doaj_org_article_a7cd504819dc47ea933001930f3da3ba</doaj_id><sourcerecordid>A614246120</sourcerecordid><originalsourceid>FETCH-LOGICAL-c625t-f26abf8c5dd500b275db09767fa85a582d795126362361de5dd0d0d8777969cb3</originalsourceid><addsrcrecordid>eNptkl1rFDEUhgdRbK3-AG8kIIheTE0ym4_xQijr10JB8OM6nE0yuymzk22Sqfa_-GM92611RyQXGU6e9z2cM29VPWX0lDEtX2fGtRY15bSWQqha3KuO2Uyxms-oun_wfVQ9yvmCUqY01Q-ro4ZTRRvGj6tf70L2kD2xa0hgi08hl2AzgcGRkjyUjR8K2ULBpyGT2JH5OgweFVgL-JbJj1DWZOML5IIlS2zsY_K2QE8sDNanNwRI8iXFvMVyuPIkl9FdkzGHYYVKFyyyKInJZdKluLlpAo-rBx302T-5vU-q7x_ef5t_qs8_f1zMz85rK7kodcclLDtthXOC0iVXwi1pq6TqQAsQmjvVCsZlI3kjmfPIUTxaKdXK1i6bk2qx93URLsw2hQ2kaxMhmJtCTCsDCSfrvQFlsclMs9bZmfLQNg2utW1o1zholoBeb_de23GJk1ncUIJ-Yjp9GcLarOKVUZS3Qms0eHlrkOLl6HMxm5Ct73sYfByz4Y3QQivNOKLP_0Ev4pgGXNWOUhJ_t5J_qRXgAGHoIva1O1NzJtmMzyTjFKnT_1B4nN8EGwffBaxPBK8mAmSK_1lWMOZsFl-_TNkXB-zaQ1_WOfZjCXHIU5DtQYthycl3d4tj1Owyb_aZN5h5s8u8Eah5drjxO8WfkDe_Ad5I_L4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2357617876</pqid></control><display><type>article</type><title>Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central</source><creator>Xu, Ruihua ; Wang, Wei ; Zhu, Bo ; Lin, Xiaoyan ; Ma, Dong ; Zhu, Lingjun ; Zhao, Qingchuan ; Nie, Yongzhan ; Cai, Xiaohong ; Li, Qi ; Fang, Weijia ; Li, Hongyan ; Wang, Ning ; Chen, Yun ; Peng, Cike ; Fang, Honghao ; Shen, Lin</creator><creatorcontrib>Xu, Ruihua ; Wang, Wei ; Zhu, Bo ; Lin, Xiaoyan ; Ma, Dong ; Zhu, Lingjun ; Zhao, Qingchuan ; Nie, Yongzhan ; Cai, Xiaohong ; Li, Qi ; Fang, Weijia ; Li, Hongyan ; Wang, Ning ; Chen, Yun ; Peng, Cike ; Fang, Honghao ; Shen, Lin</creatorcontrib><description>Colorectal cancer (CRC) is the third most prevalent cancer in China but few large-scale studies were conducted to understand CRC patients. The current study is aimed to gain a real-world perspectives of CRC patients in China. Using electronic medical records of sampled patients between 2011 and 2016 from 12 hospitals in China, a retrospective cohort study was conducted to describe demographics and disease prognosis of CRC patients, and examine treatment sequences among metastatic CRC (mCRC) patients. Descriptive, comparative and survival analyses were conducted. Among mCRC patients (3878/8136, 48%), the fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and other oxaliplatin-based regimens were the most widely-used first-line treatment (42%). Fluorouracil, leucovorin, irinotecan (FOLFIRI) and other irinotecan-based regimens dominated the second-line (40%). There was no a dominated regimen for the third-line. The proportion of patients receiving chemotherapy with targeted biologics increased from less than 20% for the first- and second- lines to 34% for the third-line (p &lt; 0.001). The most common sequence from first- to second-line was from FOLFOX and other oxaliplatin-based regimens to FOLFIRI and other irinotecan-based regimens (286/1200, 24%). Our findings reflected a lack of consensus on the choice of third-line therapy and limited available options in China. It is evident o continue promoting early CRC diagnosis and to increase the accessibility of treatment options for mCRC patients. As the only nationwide large-scale study among CRC and mCRC patients before more biologics became available in China, our results can also be used as the baseline to assess treatment pattern changes before and after more third-line treatment were approved and covered into the National Health Insurance Plan in China between 2017 and 2018.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-020-6557-5</identifier><identifier>PMID: 32070312</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>5-Fluorouracil ; Age ; Biological products ; Cancer ; Cancer metastasis ; Cancer patients ; Cancer research ; Cancer therapies ; Care and treatment ; Chemotherapy ; China ; Colorectal cancer ; Colorectal carcinoma ; Comparative analysis ; Demography ; Diseases ; Electronic medical records ; Electronic records ; Epidemiology ; Fluorouracil ; Folinic acid ; Hospitals ; Insurance ; Internal medicine ; Irinotecan ; Medical prognosis ; Medical records ; Medical research ; Metastases ; Metastasis ; National health insurance ; Oncology ; Oxaliplatin ; Patients ; Population ; Prognosis ; Real-world evidence ; Treatment patterns</subject><ispartof>BMC cancer, 2020-02, Vol.20 (1), p.131-131, Article 131</ispartof><rights>COPYRIGHT 2020 BioMed Central Ltd.</rights><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s). 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c625t-f26abf8c5dd500b275db09767fa85a582d795126362361de5dd0d0d8777969cb3</citedby><cites>FETCH-LOGICAL-c625t-f26abf8c5dd500b275db09767fa85a582d795126362361de5dd0d0d8777969cb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029588/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2357617876?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,36994,44571,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32070312$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Ruihua</creatorcontrib><creatorcontrib>Wang, Wei</creatorcontrib><creatorcontrib>Zhu, Bo</creatorcontrib><creatorcontrib>Lin, Xiaoyan</creatorcontrib><creatorcontrib>Ma, Dong</creatorcontrib><creatorcontrib>Zhu, Lingjun</creatorcontrib><creatorcontrib>Zhao, Qingchuan</creatorcontrib><creatorcontrib>Nie, Yongzhan</creatorcontrib><creatorcontrib>Cai, Xiaohong</creatorcontrib><creatorcontrib>Li, Qi</creatorcontrib><creatorcontrib>Fang, Weijia</creatorcontrib><creatorcontrib>Li, Hongyan</creatorcontrib><creatorcontrib>Wang, Ning</creatorcontrib><creatorcontrib>Chen, Yun</creatorcontrib><creatorcontrib>Peng, Cike</creatorcontrib><creatorcontrib>Fang, Honghao</creatorcontrib><creatorcontrib>Shen, Lin</creatorcontrib><title>Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>Colorectal cancer (CRC) is the third most prevalent cancer in China but few large-scale studies were conducted to understand CRC patients. The current study is aimed to gain a real-world perspectives of CRC patients in China. Using electronic medical records of sampled patients between 2011 and 2016 from 12 hospitals in China, a retrospective cohort study was conducted to describe demographics and disease prognosis of CRC patients, and examine treatment sequences among metastatic CRC (mCRC) patients. Descriptive, comparative and survival analyses were conducted. Among mCRC patients (3878/8136, 48%), the fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and other oxaliplatin-based regimens were the most widely-used first-line treatment (42%). Fluorouracil, leucovorin, irinotecan (FOLFIRI) and other irinotecan-based regimens dominated the second-line (40%). There was no a dominated regimen for the third-line. The proportion of patients receiving chemotherapy with targeted biologics increased from less than 20% for the first- and second- lines to 34% for the third-line (p &lt; 0.001). The most common sequence from first- to second-line was from FOLFOX and other oxaliplatin-based regimens to FOLFIRI and other irinotecan-based regimens (286/1200, 24%). Our findings reflected a lack of consensus on the choice of third-line therapy and limited available options in China. It is evident o continue promoting early CRC diagnosis and to increase the accessibility of treatment options for mCRC patients. As the only nationwide large-scale study among CRC and mCRC patients before more biologics became available in China, our results can also be used as the baseline to assess treatment pattern changes before and after more third-line treatment were approved and covered into the National Health Insurance Plan in China between 2017 and 2018.</description><subject>5-Fluorouracil</subject><subject>Age</subject><subject>Biological products</subject><subject>Cancer</subject><subject>Cancer metastasis</subject><subject>Cancer patients</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>China</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Comparative analysis</subject><subject>Demography</subject><subject>Diseases</subject><subject>Electronic medical records</subject><subject>Electronic records</subject><subject>Epidemiology</subject><subject>Fluorouracil</subject><subject>Folinic acid</subject><subject>Hospitals</subject><subject>Insurance</subject><subject>Internal medicine</subject><subject>Irinotecan</subject><subject>Medical prognosis</subject><subject>Medical records</subject><subject>Medical research</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>National health insurance</subject><subject>Oncology</subject><subject>Oxaliplatin</subject><subject>Patients</subject><subject>Population</subject><subject>Prognosis</subject><subject>Real-world evidence</subject><subject>Treatment patterns</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkl1rFDEUhgdRbK3-AG8kIIheTE0ym4_xQijr10JB8OM6nE0yuymzk22Sqfa_-GM92611RyQXGU6e9z2cM29VPWX0lDEtX2fGtRY15bSWQqha3KuO2Uyxms-oun_wfVQ9yvmCUqY01Q-ro4ZTRRvGj6tf70L2kD2xa0hgi08hl2AzgcGRkjyUjR8K2ULBpyGT2JH5OgweFVgL-JbJj1DWZOML5IIlS2zsY_K2QE8sDNanNwRI8iXFvMVyuPIkl9FdkzGHYYVKFyyyKInJZdKluLlpAo-rBx302T-5vU-q7x_ef5t_qs8_f1zMz85rK7kodcclLDtthXOC0iVXwi1pq6TqQAsQmjvVCsZlI3kjmfPIUTxaKdXK1i6bk2qx93URLsw2hQ2kaxMhmJtCTCsDCSfrvQFlsclMs9bZmfLQNg2utW1o1zholoBeb_de23GJk1ncUIJ-Yjp9GcLarOKVUZS3Qms0eHlrkOLl6HMxm5Ct73sYfByz4Y3QQivNOKLP_0Ev4pgGXNWOUhJ_t5J_qRXgAGHoIva1O1NzJtmMzyTjFKnT_1B4nN8EGwffBaxPBK8mAmSK_1lWMOZsFl-_TNkXB-zaQ1_WOfZjCXHIU5DtQYthycl3d4tj1Owyb_aZN5h5s8u8Eah5drjxO8WfkDe_Ad5I_L4</recordid><startdate>20200218</startdate><enddate>20200218</enddate><creator>Xu, Ruihua</creator><creator>Wang, Wei</creator><creator>Zhu, Bo</creator><creator>Lin, Xiaoyan</creator><creator>Ma, Dong</creator><creator>Zhu, Lingjun</creator><creator>Zhao, Qingchuan</creator><creator>Nie, Yongzhan</creator><creator>Cai, Xiaohong</creator><creator>Li, Qi</creator><creator>Fang, Weijia</creator><creator>Li, Hongyan</creator><creator>Wang, Ning</creator><creator>Chen, Yun</creator><creator>Peng, Cike</creator><creator>Fang, Honghao</creator><creator>Shen, Lin</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200218</creationdate><title>Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China</title><author>Xu, Ruihua ; Wang, Wei ; Zhu, Bo ; Lin, Xiaoyan ; Ma, Dong ; Zhu, Lingjun ; Zhao, Qingchuan ; Nie, Yongzhan ; Cai, Xiaohong ; Li, Qi ; Fang, Weijia ; Li, Hongyan ; Wang, Ning ; Chen, Yun ; Peng, Cike ; Fang, Honghao ; Shen, Lin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c625t-f26abf8c5dd500b275db09767fa85a582d795126362361de5dd0d0d8777969cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>5-Fluorouracil</topic><topic>Age</topic><topic>Biological products</topic><topic>Cancer</topic><topic>Cancer metastasis</topic><topic>Cancer patients</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>China</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Comparative analysis</topic><topic>Demography</topic><topic>Diseases</topic><topic>Electronic medical records</topic><topic>Electronic records</topic><topic>Epidemiology</topic><topic>Fluorouracil</topic><topic>Folinic acid</topic><topic>Hospitals</topic><topic>Insurance</topic><topic>Internal medicine</topic><topic>Irinotecan</topic><topic>Medical prognosis</topic><topic>Medical records</topic><topic>Medical research</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>National health insurance</topic><topic>Oncology</topic><topic>Oxaliplatin</topic><topic>Patients</topic><topic>Population</topic><topic>Prognosis</topic><topic>Real-world evidence</topic><topic>Treatment patterns</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Ruihua</creatorcontrib><creatorcontrib>Wang, Wei</creatorcontrib><creatorcontrib>Zhu, Bo</creatorcontrib><creatorcontrib>Lin, Xiaoyan</creatorcontrib><creatorcontrib>Ma, Dong</creatorcontrib><creatorcontrib>Zhu, Lingjun</creatorcontrib><creatorcontrib>Zhao, Qingchuan</creatorcontrib><creatorcontrib>Nie, Yongzhan</creatorcontrib><creatorcontrib>Cai, Xiaohong</creatorcontrib><creatorcontrib>Li, Qi</creatorcontrib><creatorcontrib>Fang, Weijia</creatorcontrib><creatorcontrib>Li, Hongyan</creatorcontrib><creatorcontrib>Wang, Ning</creatorcontrib><creatorcontrib>Chen, Yun</creatorcontrib><creatorcontrib>Peng, Cike</creatorcontrib><creatorcontrib>Fang, Honghao</creatorcontrib><creatorcontrib>Shen, Lin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Ruihua</au><au>Wang, Wei</au><au>Zhu, Bo</au><au>Lin, Xiaoyan</au><au>Ma, Dong</au><au>Zhu, Lingjun</au><au>Zhao, Qingchuan</au><au>Nie, Yongzhan</au><au>Cai, Xiaohong</au><au>Li, Qi</au><au>Fang, Weijia</au><au>Li, Hongyan</au><au>Wang, Ning</au><au>Chen, Yun</au><au>Peng, Cike</au><au>Fang, Honghao</au><au>Shen, Lin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2020-02-18</date><risdate>2020</risdate><volume>20</volume><issue>1</issue><spage>131</spage><epage>131</epage><pages>131-131</pages><artnum>131</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>Colorectal cancer (CRC) is the third most prevalent cancer in China but few large-scale studies were conducted to understand CRC patients. The current study is aimed to gain a real-world perspectives of CRC patients in China. Using electronic medical records of sampled patients between 2011 and 2016 from 12 hospitals in China, a retrospective cohort study was conducted to describe demographics and disease prognosis of CRC patients, and examine treatment sequences among metastatic CRC (mCRC) patients. Descriptive, comparative and survival analyses were conducted. Among mCRC patients (3878/8136, 48%), the fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and other oxaliplatin-based regimens were the most widely-used first-line treatment (42%). Fluorouracil, leucovorin, irinotecan (FOLFIRI) and other irinotecan-based regimens dominated the second-line (40%). There was no a dominated regimen for the third-line. The proportion of patients receiving chemotherapy with targeted biologics increased from less than 20% for the first- and second- lines to 34% for the third-line (p &lt; 0.001). The most common sequence from first- to second-line was from FOLFOX and other oxaliplatin-based regimens to FOLFIRI and other irinotecan-based regimens (286/1200, 24%). Our findings reflected a lack of consensus on the choice of third-line therapy and limited available options in China. It is evident o continue promoting early CRC diagnosis and to increase the accessibility of treatment options for mCRC patients. As the only nationwide large-scale study among CRC and mCRC patients before more biologics became available in China, our results can also be used as the baseline to assess treatment pattern changes before and after more third-line treatment were approved and covered into the National Health Insurance Plan in China between 2017 and 2018.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>32070312</pmid><doi>10.1186/s12885-020-6557-5</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1471-2407
ispartof BMC cancer, 2020-02, Vol.20 (1), p.131-131, Article 131
issn 1471-2407
1471-2407
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a7cd504819dc47ea933001930f3da3ba
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central
subjects 5-Fluorouracil
Age
Biological products
Cancer
Cancer metastasis
Cancer patients
Cancer research
Cancer therapies
Care and treatment
Chemotherapy
China
Colorectal cancer
Colorectal carcinoma
Comparative analysis
Demography
Diseases
Electronic medical records
Electronic records
Epidemiology
Fluorouracil
Folinic acid
Hospitals
Insurance
Internal medicine
Irinotecan
Medical prognosis
Medical records
Medical research
Metastases
Metastasis
National health insurance
Oncology
Oxaliplatin
Patients
Population
Prognosis
Real-world evidence
Treatment patterns
title Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T14%3A36%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Disease%20characteristics%20and%20treatment%20patterns%20of%20Chinese%20patients%20with%20metastatic%20colorectal%20cancer:%20a%20retrospective%20study%20using%20medical%20records%20from%20China&rft.jtitle=BMC%20cancer&rft.au=Xu,%20Ruihua&rft.date=2020-02-18&rft.volume=20&rft.issue=1&rft.spage=131&rft.epage=131&rft.pages=131-131&rft.artnum=131&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-020-6557-5&rft_dat=%3Cgale_doaj_%3EA614246120%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c625t-f26abf8c5dd500b275db09767fa85a582d795126362361de5dd0d0d8777969cb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2357617876&rft_id=info:pmid/32070312&rft_galeid=A614246120&rfr_iscdi=true